The blog
Clinical trial results, TGA regulatory progress and research updates on retatrutide and the wider peptide space — explained for Australians.
29 September 2026 · ss-31 · elamipretide · mitochondria · peptide-research · hfpef
Two 2026 ZSF1 rat studies split SS-31 (elamipretide) research in half: skeletal muscle force improved, diastolic function didn't. Plus SS-31 Australia status.
Read more →26 September 2026 · ss-31 · elamipretide · dry-amd · mitochondria · clinical-trials
SS-31 (elamipretide) research in dry AMD: the phase 2 missed both primary endpoints, yet its imaging measure became the phase 3 primary. Plus Australian status.
Read more →24 September 2026 · ss-31 · elamipretide · mitochondria · regulatory · clinical-trials
SS-31 (elamipretide) won FDA accelerated approval on an intermediate endpoint. The confirmatory trial reports in 2029, and it is not on Australia's ARTG.
Read more →21 September 2026 · ss-31 · elamipretide · mitochondria · longevity · research
SS-31 (elamipretide) research: aged mice gained heart and muscle function but no epigenetic age change, plus the human trial data and Australia's ARTG status.
Read more →18 September 2026 · ss-31 · elamipretide · dry-amd · mitochondria · clinical-trials
SS-31 research update: elamipretide's dry AMD phase 2 missed both primary endpoints, yet a photoreceptor imaging measure took it to phase 3. Australia angle.
Read more →15 September 2026 · ss-31 · elamipretide · mitochondria · clinical-trials · regulation
SS-31 (elamipretide) won accelerated FDA approval on a 12-patient trial that missed both endpoints. The confirmatory phase 4 only began dosing in July 2026.
Read more →13 September 2026 · ss-31 · elamipretide · mitochondria · longevity · peptide-research
SS-31 (elamipretide) is an XPRIZE Healthspan finalist compound. What the mouse ageing data, the 2026 HFpEF study and the ARTG status actually show.
Read more →10 September 2026 · ss-31 · elamipretide · peptides · clinical-trials · tga
SS-31 (elamipretide) research in 2026: one US approval, one failed phase 3, and a dry AMD trial reading out. What the evidence shows and its Australia status.
Read more →Stay informed
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
Get the free guide + updates
Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.